compounders sue fda over ending semaglutide shortage warning news october 2025 Drug declaration Wegovy Societies take stand against off-brand – fda compounding semaglutide warning letters

Venanzi M, Savioli M, Cimino R, Gatto E, Palleschi A, Ripani G, Cicero D, Placidi E, Orvieto F, Bianchi E

Tirzepatide is ideal for adults who are carrying excess weight that is affecting their health or quality of life particularly those with a BMI of 27 or higher, especially when accompanied by weight-related conditions like high blood pressure, type 2 diabetes, or elevated cholesterol

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unapproved by the MHRA, EMA, or FDA for routine clinical use

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy , 15 , 28812892

We strive to provide accurate information and up-to-date photos, but the actual product may slightly differ from the image on the website

Beyond-use date The beyond-use date (BUD) is provided by a compounding pharmacy for compounded medications that are specially prepared or customized for an individual patient